🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The #NIAGARA trial highlights the role of durvalumab in #BladderCancer treatment. Matt Galsky The Tisch Cancer Institute joins Leslie Ballas Cedars-Sinai to discuss on UroToday. While primary endpoints were previously published showing benefits with perioperative durvalumab, this analysis focuses

Detecting ctDNA in high-risk non-muscle invasive #BladderCancer. Dan Isaac, DO, MS MSU joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss a small study where 2/10 patients had detectable ctDNA before clinical signs—both later developed mets. A promising signal, but more data

Metastasis-directed therapy improves outcomes in oligometastatic #ProstateCancer in #WOLVERINE study. Chad Tang, MD MD Anderson Cancer Center sits down with Leslie Ballas Cedars-Sinai to discuss a meta-analysis of STOMP, ORIOLE, ARTO, EXTEND & COMET-SABR trials on oligometastatic

FGFR3 inhibition in #UrothelialCancer advances with erdafitinib and TAR-210 trials. Gopa Iyer Memorial Sloan Kettering Cancer Center and Sam S. Chang MD, MBA Vanderbilt Urology discuss targeted therapy advances, including erdafitinib & TAR-210, a novel intravesical delivery system reducing systemic toxicity.

Predicting BCG therapy response in high-grade non-muscle invasive #BladderCancer. Weranja Ranasinghe Monash Health joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss research on developing an immunohistochemistry (IHC) profile to predict response to BCG in #NMIBC. #WatchNow >

#ARASENS trial analysis investigates the impact of initial PSA values on treatment response in #mHSPC. Alicia Morgans, MD, MPH Dana-Farber and Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute highlight the clinical value of ARASENS findings beyond survival data, noting they help patients plan treatment

Considerations in optimizing nadofaragene firadenovec for BCG-unresponsive #BladderCancer. David Morris Urology Associates sits down with Zach Klaassen Georgia Cancer Center to discuss the benefits of nadofaragene firadenovec, including its quarterly dosing schedule & tolerability.

Digital therapeutics for LUTS: A randomized trial of app-based treatment. Christian Gratzke Uniklinik Freiburg & Laura Wiemer, MD Kranus Health GmbH join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss an app-based randomized trial for treating lower urinary tract symptoms. This digital therapeutic delivers

Immune infiltration gene signatures predict response to gemcitabine docetaxel vs BCG in #BladderCancer. Michael O'Donnell, MD Carver College of Medicine joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss gene expression signatures and immune infiltration in response to intravesical gemcitabine/docetaxel

Adaptive radiotherapy in #BladderCancer: Phase II results from the #RAIDERII trial. Robert Huddart💙 The ICR joins Sam S. Chang MD, MBA Vanderbilt Urology to discuss. Daily imaging & tailored plans for improved treatment precision for 98% of patients with low toxicity & promising disease

Selecting patients for triplet therapy in metastatic #ProstateCancer. Oliver Sartor, MD joins Zach Klaassen to discuss treatment intensification in metastatic hormone-sensitive prostate cancer, focusing on triplet therapy selection. #WatchNow on UroToday > bit.ly/3HIenYg

#UrinaryIncontinence in gay and bisexual #ProstateCancer survivors. Kristine Talley, PhD, RN, GNP-BC University of Minnesota School of Nursing joins Diane Newman to discuss the #RESTORE study and the need for tailored treatment approaches and improved screening practices to address potential health

When should we use 18F-FDG PET? Andrei Iagaru, MD Stanford Medicine makes the case for FDG-PET in advanced #ProstateCancer 🔍 He argues it’s essential—not optional—for identifying aggressive PSMA-negative disease, optimizing #LuPSMA therapy, and explaining non-response despite

Intravesical antibody drug Conjugates for #BladderCancer. Maria Jiang Princess Margaret Cancer Centre sits down with Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss how ADCs are transforming bladder cancer care and reshaping 1L treatment, boosting neoadjuvant response rates & even sparking bladder

Dual immune activation with EG-70 targets non-muscle invasive #BladderCancer #NMIBC. Vikram M. Narayan, MD Emory Urology joins Sam S. Chang MD, MBA Vanderbilt Urology discussing detalimogene voraplasmid (EG-70), a non-viral #bladdercancer therapy activating both innate & adaptive immunity. Early

Tumor suppressor gene status refines prognosis and treatment selection in metastatic #ProstateCancer. Martino Pedrani joins Neeraj Agarwal, MD, FASCO to discuss integrating aggressive variant prostate cancer TSG status into clinical decision-making for #mHSPC patients. #WatchNow >

CORE-008 trial Cohort CX: Combining cretostimogene grenadenorepvec and gemcitabine for #BladderCancer. Trinity J. Bivalacqua Penn joins Sam S. Chang MD, MBA Vanderbilt Urology discussing the latest arm of the CORE-008 study for #NMIBC specifically in both BCG-unresponsive and BCG-exposed patients.

#SunRISe1 trial shows #TAR200 efficacy in BCG-unresponsive #BladderCancer. Félix Guerrero-Ramos sits down with Sam S. Chang MD, MBA Vanderbilt Health discussing SunRISe-1 results — TAR-200 shows 85% DFS at 6mo in BCG-unresponsive papillary-only #bladdercancer. ➡️ Similar responses in high-grade

What's the role of Primary Score in #ProstateCancer diagnosis? Michael Hofman Peter Mac Cancer Centre shares insights at #PSMAandBeyond2025! Watch to learn more about this innovative tool > bit.ly/4monaP3 PSMA and Beyond Conference Prostate Cancer Foundation UCLA UC San Francisco

The evolving treatment landscape for #NMIBC beyond BCG. Bogdana Schmidt MD, MPH Huntsman Cancer Institute joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center in discussing new frontiers in NMIBC: intravesical combos, FGFR3-targeted agents & patient-centered alternatives to radical cystectomy. #WatchNow >